Pulse Biosciences

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pulse Biosciences pivots to cardiac tech, eyes FDA device market

Pulse Biosciences reported financials, highlighted cardiac ablation technology, and pivoted towards an FDA-approved device for cellular repair, showcasing adaptability and strategic focus.
The company faces challenges in transitioning focus areas and managing financial projections but has strengths in innovation, market potential, and strategic autonomy.
Opportunities lie in licensing breakthrough technologies, commercial partnerships, regulatory milestones, and market disruption, positioning Pulse Biosciences for growth and success.
Overall, Pulse Biosciences' strategic shifts, financial prudence, and focus on innovation present a promising outlook for sustainable growth and market expansion.

Pulse Biosciences advances cardiac ablation tech with strong financials

Pulse Biosciences made notable progress in Q1 2023, showcasing financial improvements, key leadership additions, and advancements in developing innovative cardiac ablation technologies.
While facing challenges in clinical validation and regulatory processes, the company's strategic roadmap and focus on nsPFA technology position them well for future growth and success.
With a strong financial position, experienced leadership, and a clear vision for product development, Pulse Biosciences is poised to capitalize on the market opportunities in cardiac ablation.

Pulse Biosciences advances nsPFA technology in cardiac applications, boosts finances

Pulse Biosciences demonstrated strong progress in nsPFA technology for cardiac applications and showcased financial improvements.
While facing questions about study expansions and project exits, the company remains confident in its market position.
Opportunities lie in expanding nsPFA applications, leveraging positive feedback, and exploring strategic partnerships for growth.

Pulse Biosciences advances CellFX technology, reduces costs, eyes growth opportunities

Pulse Biosciences demonstrated strong performance in technology advancement, cost management, and stakeholder engagement, positioning the company for growth.
Despite challenges related to patent concerns, the company's focus on innovation, safety, and partnerships presents opportunities for expansion and market leadership.
With a solid financial position, strategic development goals, and a commitment to excellence, Pulse Biosciences is poised for continued success in the medical technology sector.

Pulse Biosciences advances innovative surgical technology with promising FDA clearances

Pulse Biosciences is optimistic about the future impact of its energy technology on surgery and emphasizes the importance of strong support structures for successful product launches.

Pulse Biosciences excels in Q2, poised for transformative medical advancements

Pulse Biosciences' Q2 2024 performance reflects progress, financial strength, and strategic focus on pivotal clinical trials.
While facing challenges such as increased costs and operational complexities, the company is well-positioned to leverage opportunities in transformative medical technologies.
With a solid financial foundation, strong leadership, and innovative products, Pulse Biosciences is poised for continued growth and market success.
Navigating regulatory hurdles and market competition will be key as the company advances its nano-PFA technology in medical treatments.

Pulse Biosciences reports Q3 loss, strengthens balance sheet for growth

Pulse Biosciences' Q3 2024 earnings call highlighted progress in medical applications, a strengthened balance sheet, and a focus on pivotal clinical studies in 2025.
While facing challenges with increased expenses and net loss, the company's innovative technology and strategic fundraising efforts position it for future growth.
Opportunities lie in advancing clinical studies, expanding product applications, and solidifying its presence in the healthcare market through strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX® System. The data generated from this study is intended to support a 510(k) submission to expand the indication for use of the CellFX System specifica

Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced the receipt of Medical Device Single Audit Program certification. The Medical Device Single Audit Program (MDSAP) allows the conduct of a single regulatory audit of a medical device manufacturer’s quality management system to satisfy the requirements of multiple regulatory jurisdictions or authorities to enable appr

Pulse Biosciences Announces Receipt of MDSAP Certification

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2020 Results - Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

Pulse Biosciences Reports Second Quarter 2020 Financial Results

Pulse Biosciences, Inc. Appoints Richard van den Broek to Board of Directors

Pulse Biosciences Schedules Second Quarter 2020 Financial Results Conference Call for August 10, 2020

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, today announced that three clinical studies demonstrating positive results across its dermatologic portfolio are available via webcast at the virtual annual conference of the American Society for Laser Medicine and Surgery (ASLMS). The virtual meeting went live on the ASLMS website on June 30, 2020. The clinical studies span the Com

Nano-Pulse Stimulation™ Technology Produces Favorable Results in Several Clinical Studies Presented at the 2020 Laser Medicine and Surgery Virtual Annual Conference

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q1 2020 Results - Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Darrin Uecker on Q4 2019 Results - Earnings Call Transcript

Pulse Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

Pulse Biosciences Sees Hammer Chart Pattern: Time to Buy?

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2019 Results - Earnings Call Transcript

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q2 2019 Results - Earnings Call Transcript

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2019 Results - Earnings Call Transcript

Pulse BioSciences is the second instance Bob Duggan has taken the helm of a biotech that has fallen flat in an attempt to reinvigorate it.

News for Pulse Biosciences Stock (PLSE)